Efficacy of nanoparticles containing irinotecan prepared using poly(DL-lactic acid) and poly(ethylene glycol)-poly(propylene glycol)-poly(ethylene glycol) against M5076 tumor in the early liver metastatic stage

S.T.P. Pharma Sciences

Volumn 13, Issue 4, 2003, Pages 225-230

  Machida, Y ^a,b   Onishi, H ^b   Kato, Y ^b  

^a Hachioji Digestive Disease Hospital   (Japan)

^b HOSHI UNIVERSITY   (Japan)

Author keywords

Administration schedule; Irinotecan; M5076 tumor; Nanoparticle; Poly(DL lactic acid); Poly(ethylene glycol) poly(propylene glycol) poly(ethylene glycol)

Indexed keywords

ACETONE; IRINOTECAN; MACROGOL; NANOPARTICLE; POLY(PROPYLENE GLYCOL); POLYLACTIC ACID; POLYMER; POLYPROPYLENE; UNCLASSIFIED DRUG; WATER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY WEIGHT; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSAGE FORM; DRUG EFFICACY; LIVER METASTASIS; MALE; MOUSE; NONHUMAN; PARTICLE SIZE; PRECIPITATION;

EID: 0242381936     PISSN: 11571489     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. KANEDA N., NAGATA H., FURUTA T., YOKOKURA T. - Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. - Cancer Res., 50, 1715-1720, 1990.
2. KANEDA N., YOKOKURA T. - Nonlinear pharmacokinetics of CPT-11 in rats. - Cancer Res., 50, 1721-1725, 1990.
3. KAWATO Y., AONUMA M., HIROTA Y., KUGA H., SATO K. - Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. - Cancer Res., 51, 4187-4191, 1991.
4. RIVORY L. P., CHATELUT E., CANAL P., MATHIEU-BOUE A., ROBERT J. - Kinetics of the in vivo interconversion of the carboxylate and lactone forms of irinotecan (CPT-11) and its metabolite SN-38 in patients. - Cancer Res., 54, 6330-6333, 1994.
5. RIVORY L. R., BOWELS M. R., ROBERT J. and POND S. M. - Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hyrdoxycamptothecin (SN-38), by human liver carboxyesterase. - Biochem. Pharmacol., 52, 1103-1111, 1996.
6. TSUJI T., KANEDA N., KADO K., YOKOKURA T., YOSHIMOTO T., TSURU D. - CPT-11 converting enzyme from rat serum: purification and some properties. - J. Pharmacobio-Dyn., 14, 341-349, 1991.
7. SATOH T., HOSOKAWA M., ATSUMI R., SUZUKI W., HAKUSUI H., NAGAI E. - Metabolic activation of CPT-11, 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin, a novel antitumor agent, by carboxyesterase. - Biol. Pharm. Bull., 17, 662-664, 1994.
8. NAGATA H. - Flow cytometric analysis of the effect of an antitumor alkaloid, camptothecin on cell cycle progression of KB cell, J. Aichi Me. Univ. Assoc., 15, 683-699, 1987.
9. OKADA K., ANDOH T. - Topoisomerase I and II and the inhibitors to them. - Antibiotics & Chemotherapy, 9, 221-228, 1993.
10. INABA M. - Kinetic analysis of cell-killing action of DNA topoisomerase I and II inhibitors. - Abstract of Research Works for the General Research A of Subject Number 05302061 with Grantin-Aid for Scientific Research from the Ministry of Education, Science, Sports and Culture of Japan, 1994, pp. 57-61.
11. NITTA K., YOKOKURA T., SAWADA S., KUNIMOTO T., TANAKA T., UEHARA N., BABA H., TAKEUCHI M., MIYASAKA T., MUTAI M. - Antitumor activity of novel derivatives of camptothecin. - Jpn. J. Cancer Chemother., 14, 850-857, 1987.
12. FURUTA T., YOKOKURA T., MUTAI M. - Antitumor activity of CPT-11 against rat Walker 256 carcinoma. - Jpn. J. Cancer Chemother., 15, 2757-2760, 1988.
13. FURUTA T., YOKOKURA T. - Effect of administration schedules on the antitumor activity of CPT-11, a camptothecin derivative. - Jpn. J. Cancer Chemother., 17, 121-130, 1990.
14. ARAKI E., ISHIKAWA M., IIGO M., KOIDE T., ITABASHI M., HOSHI A. - Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11. - Jpn. J. Cancer Res., 84, 697-702, 1993.
15. GUPTA E., LESTINGI T. M., MICK R., RAMIREZ J., VOKES E. E., RATAIN M. J. - Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. - Cancer Res., 54, 3723-3725, 1994.
16. TAKASUNA K., HAGIWARA T., HIROHASHI M., KATO M., NOMURA M., NAGAI E., YOKOI T., KAMATAKI T. - Involvement of b-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride. - Cancer Res., 56, 3752-3757, 1996.
17. MACHIDA Y., ONISHI H., MORIKAWA A., MACHIDA Y., - Antitumor characteristics of poly(d,l-lactic acid-coglycoric acid) copolymer implant tablets containing irinotecan hydrochloride (CPT-11). - Jpn. J. Hosp. Pharm., 24, 175-181, 1998.
18. MACHIDA Y., ONISHI H., MORIKAWA A., MACHIDA Y., - Antitumor characteristics of irinotecan-containing microspheres of poly-d,l-lactic acid or poly(d,l-lactic acid-co-glycolic acid) copolymers. - STP Pharma Sci., 8, 175-181, 1998.
19. MACHIDA Y., ONISHI H., KURITA A., HATA H., MORIKAWA A., MACHIDA Y. - Pharmacokinetics of prolonged-release CPI:11-loaded microspheres in rats. - J. Control. Release, 66, 159-175, 2000.
20. ONISHI H., MACHIDA Y., MACHIDA Y. - Antitumor effect of irinotecan-containing nanoparticles prepared using poly(DL-lactic acid) and poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol). - Biol. Pharm. Bull., 26, 116-119, 2003.
21. DUNN S.E., COONBES A.G.A., GARNETT M.C., DAVIS S.S., DAVOES M.C., ILLUM L. - In vitro cell interaction and in vivo biodistribution of poly(lactide-co-glycolide) nanospheres surface modified by poloxamer and poloxamine copolymers. - J. Control. Release, 44, 65-76, 1997.
22. HART I.R., TALMADGE J.E., FIDLER I.J. - Metastatic behavior of a murine reticulum cell sarcoma exhibiting organ-specific growth. - Cancer Res., 41, 1281-1287, 1981.
23. YACHI K., SUZUKI N., TANAKA N., OKADA K., MITSUI I., KAWATO Y., KOMAGATA Y., KOMIYAMA K., KIKUCHI H. - The effect of adriamycin against a liver metastatic model by encapsulation in liposomes. - Biopharm. Drug Disposit., 17, 699-715, 1996.
24. DUNCAN R., SEYMOUR L. W., O'HARE K. B., FLANAGAN R A., WEDGE S., HUME I. C., ULBRICH K., STROHALM J., SUBR V., SPREAFICO F., GRANDI M., PIPAMONTI M., FARAO M., SUARATO A. - Preclinical evaluation of polymer-bound doxorubicin. - J. Control. Release, 19, 331-346, 1992.
25. KATO Y., ONISHI H., MACHIDA Y. - Lactosaminated and intact N-succinyl-chitosan as drug carriers in liver metastasis. - Int. J. Pharm., 226, 93-106, 2001.
26. KATO Y., ONISHI H., MACHIDA Y. - Efficacy of lactosaminated and intact N-succinylchitosan-mitomycin C conjugates against M5076 liver metastatic cancer. - J. Pharm. Pharmacol., 54, 529-537, 2002.
27. 141Ce-labeled microspheres from blood and distribution in specific organs following intravenous and intraarterial administration in beagle dogs. - J. Pharm. Sci., 69, 755-762, 1980.
28. YOSHIOKA T., HASHIDA M., MURANISHI S., SEZAKI H. - Specific delivery of mitomycin C to the liver, spleen and lung: nano- and microspherical carriers of gelatin. - Int. J. Pharm., 81,131-141, 1981.
29. TABATA Y., MURAKARI Y., IKADA Y. - Tumor accumulation of poly(vinyl alcohol) of different sizes after intravenous injection. - J. Control. Release, 50, 123-133, 1998.
30. KATO Y., ONISHI H., MACHIDA Y. - Tumor cell uptake of lactosaminated and intact N-succinyl-chitosans and antitumour effects of conjugates with mitomycin C. - Anticancer Res., 22, 2771-2776, 2002.
31. NGUYEN C.A., ALLEMANN E., SCHWACH G., DOELKER E., GURNY R. - Cell interaction studies of PLA-MePEG nanoparticles. - Int. J. Pharm., 254, 69-72, 2003.